Anaptysbio ANAB
NASDAQ ANAB
$56.40 -1.06 (-1.84%)
As of: Sep 4, 2026 · 1:26 PM EDT

Anaptysbio (ANAB) Profit After Tax (QoQ) (2016 - 2026)

Analysis

Anaptysbio (ANAB) Profit After Tax (QoQ) (2016 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn -
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn -
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn
10 Anaptysbio 1.62 Bn 1.33 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -206.28%
Dec 31, 2025 228.84%
Sep 30, 2025 139.26%
Jun 30, 2025 2.14%
Mar 31, 2025 -81.20%
Dec 31, 2024 33.69%
Sep 30, 2024 29.59%
Jun 30, 2024 -6.20%
Mar 31, 2024 -4.09%
Dec 31, 2023 -13.14%
Sep 30, 2023 6.37%
Jun 30, 2023 9.96%
Mar 31, 2023 -72.52%
Dec 31, 2022 28.04%
Sep 30, 2022 -9.50%
Jun 30, 2022 10.21%
Mar 31, 2022 -10.67%
Dec 31, 2021 -389.69%
Sep 30, 2021 -1,459.44%
Jun 30, 2021 97.64%